BioHarvest Sciences Inc. Common Stock
NASDAQ:BHSTAgricultural Inputs
+$0.08 today
- Market cap
- $50.25M
- Beta
- 1.33
- P/E (TTM)
- -6.6
- EPS (TTM)
- -$0.50
Volume 0.01M
Average 0.03M
BHST Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
BioHarvest Sciences Inc. Common StockNASDAQ: BHST
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $1.39M rose 12.0% year over year, ahead of the +9.0% change in trailing-twelve-month research & development. Sequentially, it rose 7.4% from the prior quarter. Over 3 fiscal years it compounded at +32.0% a year.
Context
- Research & development amounted to 15.4% of revenue in FY2025, down 3.7 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +12.0% holds above the trailing-twelve-month pace of +9.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 5.31M USD
- Year-over-year change
- +10.7%
- 4-year CAGR
- +6.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.31M | +10.7% |
| FY2024 | 2024-12-31 | 4.8M | +42.4% |
| FY2023 | 2023-12-31 | 3.37M | +46.0% |
| FY2022 | 2022-12-31 | 2.31M | -44.1% |
| FY2021 | 2021-12-31 | 4.13M | — |
Research & Development vs competitors
How BHST compares with its peers on the latest reported figures
- BHST's LTM Mar 2026 research & development of $5.46M is the 2nd highest of the 9 companies compared; the peer median is $67K.
- Its year-over-year change of +9.0% is the highest of 3, against a peer median of -28.1%.
- Research & development amounts to 15.5% of revenue for BHST, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $22.75M | -30.3% | -10.0% | 4.4% | |
| LTM Mar 2026 | $5.46M | +9.0% | +32.0% | 15.5% | |
| LTM Mar 2026 | $3.32M | -26.0% | +4.2% | 3.0% | |
USGOU.S. GoldMining Inc. | LTM Feb 2026 | $1.16M | — | — | — |
| LTM Mar 2026 | $134K | — | — | 0.2% | |
| LTM May 2025 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding BHST) | $67K | -28.1% | -2.9% | 0.0% | |
Competitors are the stored peer set for BHST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.1M | 5.5M | 12.67M | 25.19M | 34.51M |
| Cost of Revenue | 1.43M | 4.28M | 7.04M | 11.25M | 14.03M |
| Gross Profit | 670K | 1.22M | 5.63M | 13.94M | 20.48M |
| Gross Margin | 31.9% | 22.2% | 44.5% | 55.4% | 59.3% |
| Research & Development | 4.13M | 2.31M | 3.37M | 4.8M | 5.31M |
| Selling, General & Admin | 4.76M | 9.35M | 12.08M | 14.67M | 19.14M |
| Operating Expenses | 9.16M | 11.83M | 15.6M | 20.93M | 26.05M |
| Depreciation & Amortization | 385.58K | 712K | 840K | 1.25M | 1.62M |
| EBITDA | (8.64M) | (9.13M) | (9.76M) | (9.72M) | (6.71M) |
| EBITDA Margin | -410.9% | -166.0% | -77.0% | -38.6% | -19.5% |
| Operating Income | (8.49M) | (10.61M) | (9.97M) | (6.99M) | (5.58M) |
| Operating Margin | -403.9% | -193.0% | -78.6% | -27.7% | -16.2% |
| Interest Income | 0 | 0 | 0 | 0 | 54K |
| Interest Expense | 805K | 1.4M | 1.96M | 1.93M | 2.72M |
| Other Income / Expenses | (1.34M) | (624K) | (2.6M) | (5.92M) | (5.48M) |
| Income Before Tax | (9.83M) | (11.24M) | (12.56M) | (12.91M) | (11.06M) |
| Pre-Tax Margin | -467.5% | -204.4% | -99.1% | -51.2% | -32.0% |
| Income Tax Expense | 0 | 0 | 0 | 8K | 76K |
| Net Income | (9.83M) | (11.24M) | (12.56M) | (12.91M) | (11.14M) |
| Net Margin | -467.5% | -204.4% | -99.1% | -51.3% | -32.3% |
| EPS (Basic) | (0.70) | (0.70) | (0.93) | (0.80) | (0.60) |
| EPS (Diluted) | (0.70) | (0.70) | (0.93) | (0.80) | (0.60) |
| Weighted Avg Shares | 12.45M | 13.05M | 13.53M | 16.19M | 18.41M |
| Weighted Avg Shares (Diluted) | 12.45M | 13.05M | 13.53M | 16.19M | 18.41M |
BioHarvest Sciences Inc. Common Stock
NASDAQ:BHST
Intrinsic Alpha fair value
Locked
Current Price
$2.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.